Joseph Skitzki
Overview
Explore the profile of Joseph Skitzki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swetter S, Johnson D, Albertini M, Barker C, Bateni S, Baumgartner J, et al.
J Natl Compr Canc Netw
. 2024 Jul;
22(5):290-298.
PMID: 39019054
The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant...
2.
Rog C, Puzanov I, Skitzki J
JAMA Surg
. 2024 Feb;
159(4):361-362.
PMID: 38416463
No abstract available.
3.
Byrwa D, Twist C, Skitzki J, Repasky E, Ham 3rd P, Gupta A
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345152
Hyperthermic intraperitoneal chemotherapy (HIPEC) can directly target microscopic peritoneal disease, has achieved regular consideration in the treatment of several adult cancer types, and is more recently being studied in pediatrics....
4.
Mark J, Fisher D, Kim M, Emmons T, Khan A, Alqassim E, et al.
Gynecol Oncol
. 2022 Nov;
168:92-99.
PMID: 36410228
Objectives: Standard chemotherapy agents, including carboplatin, have known immunogenic properties. We sought to determine how carboplatin may influence lymphocyte trafficking to tumor sites. Methods: Murine models of ovarian cancer were...
5.
Lee J, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, et al.
Mol Ther Oncolytics
. 2022 May;
25:174-188.
PMID: 35592387
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation...
6.
Patel A, Skitzki J
J Surg Oncol
. 2021 Dec;
125(1):38-45.
PMID: 34897704
Adjuvant systemic therapy for cutaneous melanoma has experienced practice-changing shifts over the last decade. The successful results of immunotherapies and targeted therapies in the metastatic setting have allowed for investigative...
7.
Swetter S, Thompson J, Albertini M, Barker C, Baumgartner J, Boland G, et al.
J Natl Compr Canc Netw
. 2021 Apr;
19(4):364-376.
PMID: 33845460
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections:...
8.
Gastman B, Agarwal P, Berger A, Boland G, Broderick S, Butterfield L, et al.
J Immunother Cancer
. 2020 Nov;
8(2).
PMID: 33199512
Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on...
9.
Rao P, Barker C, Coit D, Joseph R, Materin M, Rengan R, et al.
J Natl Compr Canc Netw
. 2020 Feb;
18(2):120-131.
PMID: 32023525
The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between...
10.
Coit D, Thompson J, Albertini M, Barker C, Carson W, Contreras C, et al.
J Natl Compr Canc Netw
. 2019 Apr;
17(4):367-402.
PMID: 30959471
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor...